Liver impairment study tests cancer drug safety

NCT ID NCT06740799

Recruiting now Knowledge-focused Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the cancer drug quizartinib behaves in people with severe liver impairment compared to healthy volunteers. Twelve participants will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor for side effects. The goal is to understand dosing safety, not to treat any condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Quizartinib (a cancer drug, brand name VANFLYTA)
What this could lead to: If successful, this study could help doctors understand how to safely dose quizartinib in patients with severe liver problems.
What could go wrong: This is a very early, small study (12 people) focused on safety and drug levels, not treatment. It may not lead to any changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Advanced Pharma
RECRUITING

Miami, Florida, 33147, United States
Clinical Pharmacology of Miami, LLC
RECRUITING

Miami, Florida, 33014, United States
GCP Research
RECRUITING

St. Petersburg, Florida, 33705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.